Bibliographie : Cannabinoïdes synthétiques et Néocannabinoïdes Dr Christian Sueur, GRECC, décembre 2020 Définitions et Usages des cannabinoïdes synthétiques : 2 - 6 Toxicologie des cannabinoïdes synthétiques : 7– 12 Cannabinoïdes synthétiques et psychose : 11 - 12 Pharmacologie des cannabinoïdes synthétiques : 13 - 16 Neurophysiologie des cannabinoïdes synthétiques : 17 -18 Analyse des cannabinoïdes synthétiques : 18 - 19 Usage médical des cannabinoïdes synthétiques : 20 – 22 Rimonabant : 21 -22
Lire la suiteThe potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health Sam Gandy, Matthias Forstmann, Robin Lester Carhart-Harris, Christopher Timmermann, David Luke and Rosalind Watts Health Psychology Open, 2020, 1–21 Doi : 10.1177/2055102920978123 Abstract Therapeutic psychedelic administration and contact with nature have been associated with the same psychological mechanisms : decreased rumination and negative affect, enhanced psychological connectedness and mindfulness related capacities, and heightened states of awe and transcendent experiences, all processes linked to improvements in mental health amongst clinical and healthy populations. Nature-based settings can have inherently psychologically soothing properties which may complement all stages of psychedelic therapy (mainly [...]
Lire la suiteEffects of external stimulation on psychedelic state neurodynamics Pedro A.M. Mediano, Fernando E. Rosas, Christopher Timmermann, Leor Roseman, David J. Nutt, Amanda Feilding, Mendel Kaelen, Morten L. Kringelbach, Adam B. Barretti, Anil K. Seth, Suresh Muthukumaraswamy, Daniel Bor, and Robin L. Carhart-Harris bioRxiv preprint, 2020 doi : 10.1101/2020.11.01.356071 Abstract Recent findings have shown that psychedelics reliably enhance brain entropy (understood as neural signal diversity), and this effect has been associated with both acute and long-term psychological outcomes such as personality changes. These findings are particularly intriguing given that a decrease of brain entropy is a robust indicator of loss of consciousness (e.g. from wakefulness to [...]
Lire la suiteTroubles anxieux : le CBD peut soulager les symptômes Kalapa Clinic, Barcelone, Espagne By Gesa|30/06/2020 La peur est une réaction naturelle à certaines situations et à certains événements. Elle remplit à la fois une fonction d’avertissement et de protection. Lors d’un trouble anxieux, cependant, elle développe une dynamique propre qui est très stressante pour les personnes concernées. Diverses études et rapports d’expérience indiquent que le cannabinoïde non-psychoactif cannabidiol (CBD) peut soulager leurs symptômes. En Allemagne, le trouble anxieux est la maladie mentale la plus courante, devançant même la dépression. Environ 12 millions de personnes sont touchées, les femmes plus souvent que les hommes (1). Le [...]
Lire la suiteEarly phytocannabinoid chemistry to endocannabinoids and beyond Raphael Mechoulam, Lumír O. Hanuš, Roger Pertwee and Allyn C. Howlett NATURE REVIEWS | NEUROSCIENCE, 2014, 15, 757-764. Doi : 10.1038/nrm3811 Abstract Isolation and structure elucidation of most of the major cannabinoid constituents — including Δ9-tetrahydrocannabinol (Δ9-THC), which is the principal psychoactive molecule in Cannabis sativa — was achieved in the 1960s and 1970s. It was followed by the identification of two cannabinoid receptors in the 1980s and the early 1990s and by the identification of the endocannabinoids shortly thereafter. There have since been considerable advances in our understanding of the endocannabinoid system and its function in the [...]
Lire la suiteUse of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia Nathan A. Gillespie, Kenneth S. Kendler JAMA Psychiatry, Published online November 4, 2020 Cohort studies and meta-analyses have documented a robust association between cannabis use, heavy use, and misuse with future risk of schizophrenia.1-3 Despite adjusting for covariates, including current psychotic symptoms, other psychopathology, and social integration,(1) the ability of these models to determine the degree to which cannabis causes schizophrenia is limited and dependent on their ability to capture all relevant confounders. When evaluating efforts to reduce cannabis use as a means of [...]
Lire la suitePsychedelics as a Treatment for Alzheimer’s Disease Dementia Simon Andrew Vann Jones and Allison O’Kelly Cornwall Partnership NHS Foundation Trust, Liskeard, United Kingdom Frontiers in Synaptic Neuroscience, August 2020 | Volume 12 | Article 34 doi : 10.3389/fnsyn.2020.00034 Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic [...]
Lire la suiteRole of the endogenous cannabinoid system in nicotine addiction : novel insights Islam Hany Gamaleddin, Jose M.Trigo, Aliou B. Gueye, Alexander Zvonok, Alexandros Makriyannis, Steven R. Goldberg and Bernard Le Foll Frontiers in Psychiatry, 2015, Vol 6, Article 41, 1-12. doi : 10.3389/fpsyt.2015.00041 Several lines of evidence have shown that the endogenous cannabinoids are implicated in several neuropsychiatric diseases. Notably, preclinical and human clinical studies have shown a pivotal role of the cannabinoid system in nicotine addiction. The CB1 receptor inverse agonist/antagonist rimonabant (also known as SR141716)was effective to decrease nicotine-taking and nicotine-seeking in rodents, as well as the elevation of dopamine induced by [...]
Lire la suiteCannabinomimetric Lipids : From Natural Extract to Artificial Synthesis Ya-Ru Gao, Yong-Qiang Wang Natural Products and Bioprospecting, 2018, 8, 1–21 doi : 10.1007/s13659-017-0151-9 Abstract Endocannabinoid system is related with various physiological and cognitive processes including fertility, pregnancy, during pre- and postnatal development, pain-sensation, mood, appetite, and memory. In the latest decades, an important milestone concerning the endocannabinoid system was the discovery of the existence of the cannabinoid receptors CB1 and CB2. Anandamide was the first reported endogenous metabolite, which adjusted the release of some neurotransmitters through binding to the CB1 or CB2 receptors. Then a series of cannabinomimetric lipids were extracted from marine organisms, which [...]
Lire la suiteResearch Progress of the Antiviral Bioactivities of Natural Flavonoids Lin Wang · Junke Song · Ailin Liu · Bin Xiao · Sha Li · Zhang Wen · Yang Lu · Guanhua Du Natural Products and Bioprospecting, 2020, 10, 271–283 doi : 10.1007/s13659-020-00257-x Abstract Flavonoids are now considered as an indispensable component in a variety of nutraceutical and pharmaceutical applications. Most recent researches have focused on the health aspects of flavonoids for humans. Especially, different flavonoids have been investigated for their potential antiviral activities, and several natural flavonoids exhibited significant antiviral properties both in vitro and in vivo. This review provides a survey of the literature [...]
Lire la suite